Abstract
To reverse the irreversible is the dream of every physician. In pulmonary medicine, emphysema and chronic fibrosis are examples of anatomical lesions that do not regress with existing therapies and, to date, complete prevention of progression has not been achieved. Trial endpoints have not indicated the regeneration of normal tissue or the restoration of pulmonary function in fibrotic lung disease. In idiopathic pulmonary fibrosis, nintedanib and pirfenidone attenuate, but do not prevent, disease progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
